Genentech dissolves cancer immunology group, and research executive Ira Mellman will leave company

Lei Lei Wu

News Reporter

Genentech is dismantling its cancer immunology team in a reorganization of its work in the field, and its VP of cancer immunology, Ira Mellman, will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Genentech dissolves cancer immunology group, and research executive Ira Mellman will leave company

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

FDA approves first drug to treat ultra-rare lipid storage disease

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trump blog: Judge extends nationwide block on NIH payment cuts

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Genen­tech dis­solves can­cer im­munol­o­gy group, and re­search ex­ec­u­tive Ira Mell­man will leave com­pa­ny

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Genentech dissolves cancer immunology group, and research executive Ira Mellman will leave company